NCT01436955

A Study of RG1662 in Individuals With Down Syndrome

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Investigate Safety and Tolerability of RG1662 in Individuals With Down Syndrome

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Not accepted

Summary

This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is 38 days.

Conditions

• Down Syndrome

Interventions

Type	Name	Description
DRUG	Placebo	multiple oral doses
DRUG	RG1662	Cohorts receiving multiple oral doses

Timeline

• Start date: 2011-11-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2011-09-20
• Last updated: 2015-03-03

Locations

9 sites across 2 countries: United States, United Kingdom